🇺🇸 FDA
Patent

US 10913726

Centrally active and orally bioavailable antidotes for organophosphate exposure and methods for making and using them

granted A61KA61K31/55A61P

Quick answer

US patent 10913726 (Centrally active and orally bioavailable antidotes for organophosphate exposure and methods for making and using them) held by The Regents of the University of California expires Mon Feb 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Feb 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
22
CPC classes
A61K, A61K31/55, A61P, A61P25/00